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Diabetes and Vascular
18F-Fluorodeoxyglucose
Positron Emission
Tomography Uptake
Another Step Toward Understanding
Inflammation in Atherosclerosis*
John O. Prior, MD, PHD
Lausanne, Switzerland
Atherosclerosis remains the leading cause of death in North
America and Europe. During the natural course of athero-
sclerosis, inflammation plays a major role in the develop-
ment of complex plaque lesions containing activated mac-
rophages, foam cells, T lymphocytes, mast cells, and a
necrotic lipid-rich core (1). When such a plaque becomes
unstable due to uncontrolled inflammation and thinning of the
matrix-rich fibrous cap, it can suddenly rupture, triggering
thrombotic vessel occlusion leading to the clinical expression of
a stroke or a myocardial infarction. Type 2 diabetes mellitus is
a complex disease, with disturbances in glucose and lipid
metabolism and systemic inflammation. It is an established
risk for atherosclerosis and increases the prevalence of stroke
and cardiovascular disease (CVD).
See page 2080
Over the last decade, imaging with 18F-fluorodeoxyglucose
18F-FDG) positron emission tomography (PET) has
merged as a powerful technique to measure local vascular
nflammation due to atherosclerosis (2,3), offering molecular
nformation, which is not available by anatomic imaging
uch as x-ray angiography, computed tomography, and
agnetic resonance imaging. Uptake of 18F-FDG-PET is
hought to represent macrophage activity in inflamed inti-
al atherosclerotic plaques (4), with a possible response of
acrophage to hypoxia (5). The 18F-FDG-PET uptake is
ransiently observed in the early phase of atherosclerosis and
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contents of this paper to disclose.egresses when plaque calcification occurs in more stable
esions (6,7). Studies investigating the association of 18F-
DG-PET uptake and cardiovascular risk factors have shown
orrelations with older age, male sex, and hypercholesterolemia
8); Framingham risk score (9); diabetes mellitus (9,10); body
ass index, insulin resistance, and C-reactive protein (11); and
atrix metalloproteinases and plaque high-risk morphological
eatures (12).
In this issue of the Journal, Bucerius et al. (13) evaluated
he impact of type 2 diabetes on carotid 18F-FDG-PET
ptake in a large population of 134 patients with docu-
ented or suspected cardiovascular disease, among which
3 patients had documented type 2 diabetes. They measured
he maximum standardized uptake value (meanSUV) aver-
ged over all slices of both common carotid arteries, the
arget-to-background ratio (meanTBR) obtained by normal-
izing SUV by jugular veins’ blood pool activity and the
single hottest slice (SHS) defined as maximum carotid
TBR. They proposed to linearly normalize these indices by
fasting blood glucose in analogy to oncologic PET (14).
They found a significant independent correlation between
these glucose-corrected indices of 18F-FDG-PET uptake
nd the presence of diabetes, although these associations
ere not observed with non–glucose-corrected indices.
Hyperglycemia is thought to decrease 18F-FDG-PET
ptake in tumors by a direct competition mechanism (15).
lthough glycolytic activity is heterogeneous and glucose
tilization varies among tumors, blood glucose correction is
ecommended in oncological PET studies (14). In fact,
hether to correct for fasting blood glucose is a matter of
lucose utilization rate (MRgluc) in the tissue being consid-
ered (16). For instance, if MRgluc is proportional to blood
lucose such as in skeletal muscle, non–glucose-corrected
UV leads to a more stable parameter independent of blood
lucose variations. On the contrary, when glucose transport or
etabolic process in tissue is highly saturated or regulated such
s in most tumors, MRgluc remains constant, while the uptake
constant is inversely proportional to blood glucose and a linear
correction of SUV by blood glucose is meaningful (16).
However, no data are yet available in vivo on MRgluc in
acrophage-induced inflammation, and more basic studies
re needed to better understand 18F-FDG-PET uptake. In
he literature, other blood glucose correction methods exist
or SUV (17,18). Serial dynamic PET acquisitions under
lucose clamping conditions may help characterize differ-
nces between tumors and inflammation regarding 18F-
DG-PET uptake, and understanding which blood glucose
orrection to apply, if required. In spite of this uncertainty,
he study by Bucerius et al. (13) is adding additional
nowledge on the effect of diabetes on carotid 18F-FDG-
PET uptake. There have been only a few studies investi-
gating the 18F-FDG-PET uptake in relation to diabetes
(9,10), in which significantly higher 18F-FDG-PET uptake
was found in diabetic patients as compared to nondiabetic
ones. Additionally, Bucerius et al. (13) found positive
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unexpected inverse correlation with positive family history
of CVD.
Carotid plaque imaging with 18F-FDG-PET is at the
orefront of cardiology: its value lies in its correlation with
linical symptoms and outcome, and its ability for therapy
onitoring. Indeed, direct in vivo visualization of the
iseased process in atherosclerosis may help identify patients
t high risk for cardiovascular events not presently identified
y clinical or laboratory examinations. Moreover, trials
sing this technology to monitor therapeutic interventions
iming at reducing vascular inflammation may help to
dentify novel therapies and risk stratification methods.
linically available radiotracers are of interest in character-
zing atherosclerosis and vascular plaque inflammation: for
xample, 11C-PK11195 shows activated macrophages in
laque inflammation (19), 18F-fluorocholine shows choline
ransport (20), and 11C-acetate measures fatty acid synthesis
in the atheroma’s lipid core (21). Molecular imaging also
probes mechanisms such as angiogenesis or apoptosis and
offering novel opportunities to characterize atherosclerosis.
Given that annually 15 million people worldwide have a
stroke, a better understanding of atherosclerosis progression
toward unstable plaque would be welcomed. The study by
Bucerius et al. (13) represents an important step in under-
standing 18F-FDG-PET uptake in relation to diabetes, and
t is timely questioning how to take into account elevated
lood glucose, thus outlining a need for further careful
nvestigations to understand the fluctuations of 18F-FDG-
ET uptake in inflammation in relation to glucose homeo-
tasis. Forthcoming prospective studies on the ability to predict
laque rupture and clinical events will help define the potential
linical utility of vascular 18F-FDG-PET imaging, but the
question of how to correct 18F-FDG-PET uptake in relation
to fasting blood glucose will arise again.
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